Cadmium and silver complexes of a pyridine containing ligand: syntheses, structural studies, biological activity and docking studies

The current study aimed to synthesize seven new metal coordination complexes (Q1-Q7) with potential biomedical applications. Novel mononuclear, polynuclear and mixed-ligand coordination compounds of the elements, cadmium(ii) and silver(i) derived from a pyridine containing ligand (2,4,6-tris-(2-pyridyl)-1,3,5-triazine (TPT)) have been synthesized successfully with the general formulae [Cd(TPT)Cl6]·H2O and [Ag x (TPT) y (L)2(ClO4)](ClO4) z (x = 1,2,3, y = 1,2,3, L = PPh3 or phen, z = 1,2). The structural features were fully characterized using various spectroscopic techniques, such as infrared, ultraviolet-visible spectroscopy, 1D and 2D-NMR (1H, 13C, 31P, 1H-1H COSY and 1H-13C HSQCAD), CHN analysis, molar conductance (Λ), thermogravimetric analysis (TGA), and powder X-ray diffraction analysis. The structure of complex Q6 was also confirmed by single-crystal X-ray analysis. The luminescence and electrochemical properties of complexes, in solution, have been studied. X-ray crystallographic determination of the [Ag(TPT)(PPh3)2]ClO4·EtOH (Q6) complex shows that the Ag+ cation is bonded to one tridentate TPT ligand through NNN set of donor atoms and two triphenylphosphine ligands, giving the Ag+ a distorted trigonal bipyramidal geometry. X-ray powder diffraction analysis showed that metal complexes Q3, Q6 and Q7 display crystalline peaks. The complexes were evaluated for their in vitro antibacterial efficacy against various bacterial and fungal species. The in vitro efficacy against the MCF-7 human breast cancer cell line was assessed to determine the anticancer activities. The tri-nuclear silver complex Q3 shows great potential as a therapeutic candidate for treating breast cancer, since it exhibits a half-maximal inhibition concentration (IC50) of 13.45 ± 0.9 μM. Molecular docking simulations were also carried out to evaluate the interaction strength and properties of the metal complexes with selected cancer and bacteria relevant proteins namely cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 6 (CDK6), signal transducer and activator of transcription 3 (STAT3), and beta-lactamases from Escherichia coli and Staphylococcus aureus.

DFT/TD-DFT study of electronic and phosphorescent properties in cycloplatinated complexes: implications for OLEDs

High level density functional and time-dependent density functional (DFT, TD-DFT) theoretical methods have been employed to investigate the photophysical properties of 5 inorganic compounds resulting from Pt(ii) and ppy (2-phenyl-pyridine) ligands. This study is intended to provide insight into the capability of the selected systems to be used in OLED devices. In addition to an exploration of their ground and excited state geometry and electronic structures, the electronic transitions responsible for their absorption and spectra, as well as other photophysical properties, have been analyzed. To this end, their charge transfer parameters, the triplet exciton generation, phosphorescence quantum yield, and radiative decay rates have been studied. Overall, the results confirm that the selected systems are promising candidates to be used in OLED devices. Moreover, the results of this study assist in understanding the photophysical properties of Pt(ii) complexes with ppy ligands.

Half-Sandwich Cyclometalated RhIII Complexes Bearing Thiolate Ligands: Biomolecular Interactions and In Vitro and In Vivo Evaluations

A class of cyclometalated RhIII complexes [Cp*Rh(ppy)(SR)] bearing thiolate ligands, Cp* = pentamethylcyclopentadienyl, ppy = 2-phenylpyridinate, and R = pyridyl (Spy, 2), pyrimidyl (SpyN, 3), benzimidazolyl (Sbi, 4), and benzothiazolyl (Sbt, 5), were produced and identified by means of spectroscopic methods. The in vitro cytotoxicity of the RhIII compounds in three different human mortal cancerous cell lines (ovarian, SKOV3; breast, MCF-7; lung, A549) and a normal lung (MRC-5) cell line were evaluated, indicating the selectivity of these cyclometalated RhIII complexes to cancer cells. Complex 5, selected for in vivo experiment, has shown an effective inhibition of tumor growth in SKOV3 xenograft mouse model relative to control (p-values < 0.05 and < 0.01). Importantly, the outcomes of H&E (hematoxylin and eosin) staining and hematological analysis revealed negligible toxicity of 5 compared to cisplatin on a functioning of the main organs of mouse. Molecular docking, UV-vis, and emission spectroscopies (fluorescence, 3D fluorescence, synchronous) techniques were carried out on 1-5 to peruse the mechanism of the anticancer activities of these complexes. The obtained data help to manifest the binding affinity between the rhodium compounds and calf thymus DNA (CT-DNA) through the interaction by DNA minor groove and moderate binding affinity with bovine serum albumin (BSA), particularly with the cavity in the subdomain IIA. It can be concluded that the Rh-thiolate complexes are highly promising leads for the development of novel effective DNA-targeted anticancer drugs.

Half-lantern Cyclometalated Platinum(II) Complexes as Anticancer Agents: Molecular docking, Apoptosis, Cell Cycle Analysis and Cytotoxic Activity Evaluations

BACKGROUND AND OBJECTIVE

In the design of modern metal-based anticancer drugs, platinum-based complexes have gained growing interest. In this study, the anticancer activity of half-lantern cyclometalated Pt(II)‒Pt(II) complexes were was evaluated using MTT, apoptosis, cell cycle analysis, and DNA binding studies.

MATERIALS AND METHODS

The cytotoxicity of Pt(II)‒Pt(II) complexes were evaluated against different cancer cell lines such as human lung (A549), breast (MCF-7, and MDA-MB-231), ovarian (SKOV-3), and colon (HT-29) as well as normal breast (MCF-10A), and human lung fibroblast MRC-5 cells using MTT assay. BioLegend's PE Annexin V Apoptosis Detection Kit with 7AAD was applied to assess the apoptotic effects of 1A, and 1B compound against MCF-7, and A549 cell lines. Cell cycle analysis was determined using the flowcytometry method. The interaction of compounds with four different DNA structures with PDB codes (1BNA, 1LU5, 3CO3, and 198D) has been investigated by molecular docking. To achieve binding to DNA experimentally, the electrophoresis mobility shift assay and comet assay was applied.

RESULTS

In the evaluation of cytotoxic effects, 1A showed the highest cytotoxicity among the studied compounds, and it showed higher potency with more selectivity against normal cell lines than cisplatin. This compound had IC50 of 7.24, 2.21, 1.18, 2.71, 10.65, 18.32 and 49.21 μM against A549, SKOV3, HT29, MCF-7, MDA-MB-231, MRC-5, and MCF-10A, respectively, whereas cisplatin had IC50 of 9.75, 19.02, 107.23, 15.20, 18.09, 14.36, and 24.21 μm, respectively, on the same cell lines. In order to check the DNA binding activity of 1A, and 1B, electrophoretic mobility was also conducted, which indicated that the binding of these compounds led to a slight change in electrophoretic mobility to DNA. The migration of chromosomal DNA from the nucleus in the form of a tail or comet was executed in the comet assay of 1A on MCF-7. Examination of apoptosis of 1A, and 1B on the MCF-7 cancer cell line, showed that it could increase induction of apoptosis in this cancerous cell in a concentration-dependent manner. Investigating the effect of 1A using cell cycle analysis on MCF-7 cancer cell line showed that this complex affects the stage G1 and S of the cell cycle.

CONCLUSION

1A has the potential to play a significant role in future biopharmaceutical studies.

A C^N Cycloplatinated(II) Fluoride Complex: Photophysical Studies and Csp3-F Bond Formation

This work reports the synthesis and characterization of a new C^N-based cycloplatinated(II) fluoride complex, [Pt(ppy)(PPh₃)F] (2; ppy = 2-phenylpyridinate), involving a Pt-F bond. The new complex is highly luminescent in the green area with a high quantum yield of 94.6% at 77 K. A comparison study of the heavier halogen derivatives reveals a descending emission quantum yield order of F > Cl > Br > I. Time-dependent density functional theory calculations ascribe the decreased emission efficiency to the decreasing trend of an intraligand (IL) transition from F to I, which accounts for the major radiative pathway. In addition, 2 is capable of the fluorinating alkyl halides, leading to C_sp³-F bond formation at room temperature.

Half-lantern cyclometalated Pt(ii) and Pt(iii) complexes with bridging heterocyclic thiolate ligands: synthesis, structural characterization, and electrochemical and photophysical properties

Half-lantern Pt(ii) and Pt(iii) cyclometalated binuclear complexes, bridged with various heterocyclic thiolate ligands, were synthesized and studied by electrochemical and photophysical techniques.

The influence of thiolate ligands on the luminescence properties of cycloplatinated(ii) complexes

Complexes [Pt(C^{^}N)(PPh₃)Cl] (C^{^}N = bzq (7,8-benzoquinolinyl, A) and ppy (2-phenylpyridinyl, B)) were reacted with various thiolate ligands to afford complexes [Pt(C^{^}N)(PPh₃)(κ¹-S-SR)], C^{^}N = bzq, R = SPh (thiophenolate, 1a); C^{^}N = ppy, R = SPh (1b); C^{^}N = bzq, R = Spy (pyridine-2-thiolate, 2a); C^{^}N = ppy, R = Spy (2b); C^{^}N = bzq, R = SpyN (pyrimidine-2-thiolate, 3a); C^{^}N = ppy, R = SpyN (3b). Complexes 1-3 were characterized by NMR spectroscopy, and the solid-state structures of 1a and 2a were determined by X-ray diffraction methods. Replacing a chloride ligand with electron-rich thiolates changes the lowest energy singlet and triplet excited states to the ones that feature charge transfer from the thiolate (mixed with some metal character) to the C^{^}N ligand, which was supported by TD-DFT calculations. All complexes are emissive at 298 K in the solid state except 2b and 3b, which are emissive only at 77 K having a less rigid structure compared to others. The emission of 1a and 1b originates from a low-energy excited state of d_Pt/π_SR → π*_C^N while 3a exhibits a ³LC/³MLCT transition. For 1a and 1b, the radiative rate and the quantum efficiency are higher in a rigid environment such as a solid compared to a polymer and solution. Decreasing the rigidity of the environment leads to a flexibility of rotation of the -SR around the axis of the Pt-S bond. So the geometry can be easily changed after radiation and the lowest lying triplet excited state would have the effective contribution of the dd* transition, which opens a nonradiative pathway at room temperature.

Cyclometalated platinum(ii) complexes of 2,2'-bipyridine N-oxide containing a 1,1'-bis(diphenylphosphino)ferrocene ligand: structural, computational and electrochemical studies

The preparation and characterization of new heteronuclear-platinum(ii) complexes containing a 1,1'-bis(diphenylphosphino)ferrocene (dppf) ligand are described. The reaction of the known starting complex [PtMe(κ²N,C-bipyO-H)(SMe₂)], A, in which bipyO-H is a cyclometalated rollover 2,2'-bipyridine N-oxide, with the dppf ligand in a 2 : 1 ratio or an equimolar ratio led to the formation of the corresponding binuclear complex [Pt₂Me₂(κ²N,C-bipyO-H)₂(μ-dppf)], 1, or the mononuclear complex [PtMe(κ¹C-bipyO-H)(dppf)], 2, respectively. According to the reaction conditions, the dppf ligand in 1 and 2 behaves as either a bridging or chelating ligand. All complexes were characterized by NMR spectroscopy. The solid-state structure of 2 was determined by the single-crystal X-ray diffraction method and it was shown that the chelating dppf ligand in this complex was arranged in a "synclinal-staggered" conformation. Also, the occurrence of intermolecular C-H_CpO_bipyO-H interactions in the solid-state gave rise to an extended 1-D network. The electronic absorption spectra and the electrochemical behavior of these complexes are discussed. Density functional theory (DFT) was used for geometry optimization of the singlet states in solution and for electronic structure calculations. The analysis of the molecular orbital (MO) compositions in terms of occupied and unoccupied fragment orbitals in 2 was performed.

Reactivity of a new aryl cycloplatinated(ii) complex containing rollover 2,2′-bipyridine N-oxide toward a series of diphosphine ligands

A new rollover cycloplatinated(ii) complex was prepared. The reactivity of this complex was investigated towards a wide range of diphosphine ligands.

Cycloplatinated(ii) complexes bearing an O,S-heterocyclic ligand: search for anticancer drugs

Cycloplatinated(ii) complexes containing the 2-mercaptopyridine N-oxide ligand were synthesized and characterized spectroscopically. The biological activities of these complexes were also investigated.

Synthesis, Biological Evaluation, and Molecular Docking Studies on the DNA Binding Interactions of Platinum(II) Rollover Complexes Containing Phosphorus Donor Ligands

Cyclometalated rollover complexes of the type [PtMe(κ² N,C-bipyO-H)(L)] [bipyO-H=cyclometalated 2,2'-bipyridine N-oxide; L=tricyclohexylphosphine (PCy₃ , 2 a), 2-(diphenylphosphino)pyridine (PPh₂ py, 2 b), P(OPh)₃ (2 c)] were synthesized by treating [PtMe(κ² N,C-bipyO-H)(SMe₂ )] (1) with various monodentate phosphine and phosphite ligands. These complexes were characterized by NMR spectroscopy, and the structure of 2 a was confirmed by single-crystal X-ray diffraction. Complex 1 was treated with bis(diphenylphosphino)methane (dppm) at a 1:1 ratio to give the corresponding [PtMe(κ² N,C-bipyO-H)(κ¹ P-dppm)] (3 b) complex, in which the dppm ligand acts as a monodentate pendant ligand. The biological activities of these complexes were evaluated against a panel of four standard cancer cell lines: lung carcinoma (A549), ovarian carcinoma (OV-90 and SKOV3), and breast carcinoma (MCF-7). Complexes 2 c and especially 3 b indicated effective potent cytotoxic activity regarding the cell lines. Electrophoresis mobility shift assays and molecular-modeling investigations were performed to determine the specific binding mode and the binding orientation of these alkylating agents to DNA. Detection of cellular reactive oxygen species was also determined.

Photophysical properties of a series of cycloplatinated(ii) complexes featuring allyldiphenylphosphane

Cycloplatinated(ii) complexes 1–4 were synthesized and characterized. All complexes exhibit strong luminescence except 3.

Carbon–sulfur bond reductive coupling from a platinum(ii) thiolate complex

Complex 1 was reacted with different alkyl halides at room temperature. This reaction proceeded via formation of binuclear intermediate complex 3 and through C–S bond reductive coupling to produce alkyl sulfides and corresponding halide complexes 2.